hares of Cadila Healthcare added 2 percent as it has received USFDA nod for Tizanidine tablets.
Zydus Cadila has received a final approval from the USFDA to market Tizanidine tablets USP in the strength of 2 mg and 4 mg.
The drug is used to treat muscle spasms caused by certain conditions such as multiple sclerosis, spinal cord injury and works by helping to relax the muscles.
It will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.
Benchmark indices opened mildly lower on Tuesday after the January's industrial output and February's CPI inflation data announced later in the day yesterday. It was a bit of profit booking after yesterday's more than 600 points rally on the Sensex.
The 30-share BSE Sensex was down 25.52 points at 33,892.42 and the 50-share NSE Nifty fell 7.50 points to 10,413.90.
TCS was biggest loser among Nifty50 stocks, falling more than 5 percent after big block deal.
Nifty Midcap was down 38 points and Nifty Bank was flat.
UCO Bank, IDBI Bank, PNB, Canara Bank, Bank of Baroda, Balrampur Chini, Shree Renuka, Dhampur Sugar, InterGlobe Aviation and Biocon fell up to 5 percent.
Future Consumer rallied 6 percent.
Industrial output expanded at 7.5 percent in January, from 7.1 percent in previous month while retail inflation fell to a 4-month low of 4.44 percent in February from 5.07 percent in previous month.
Asian stock markets were lower as Washington's policies hit regional steel producers. The Nikkei 225, Shanghai Composite, Hang Seng and ASX 200 slipped 0.10-0.6 percent.
The S&P 500 and the Dow Jones Industrial Average slumped on Monday as the US tariffs signed into law last week by President Donald Trump weighed on industrials.
Missed call
@8817002233,WHATSAPP NO. 8602780449
Mail Us =
starindiamarket@gmail.com
No comments:
Post a Comment